The Peptide
Encyclopedia

BPC-157 is a synthetic gastric-protein-related pentadecapeptide with extensive animal repair research and limited, low-certainty human reports. Its history, preliminary clinical signals, safety unknowns and unapproved status belong alongside the mechanistic interest.

GHK-Cu is the copper-bound Gly-His-Lys tripeptide, also used cosmetically as copper tripeptide-1. Its extensive cell/animal biology, mixed topical human results and small eyebrow study do not establish systemic injectable benefits.

Retatrutide (LY3437943) is an investigational weekly GIP/GLP-1/glucagon triple agonist with large Phase 2 and Phase 3 weight-loss findings. It remains unapproved, and trial regimens or manufacturing timelines are not a prescribing label or guaranteed launch date.

Tirzepatide is a weekly dual GIP/GLP-1 receptor agonist. Mounjaro and Zepbound share the active ingredient but have separate indication, age-group and product-label contexts; evidence depends on the population and endpoint.

Semaglutide is a GLP-1 receptor agonist used in product-specific diabetes, weight-management, cardiovascular, kidney and MASH indications. Weekly injections and daily tablets contain the same active molecule but have different labels and instructions.

TB-500 commonly denotes an acetylated seven-residue fragment of thymosin beta-4. Inconsistent research-market labeling makes it essential to distinguish that fragment from the full-length parent and its clinical studies.

Tesamorelin is a GHRH analog used in specific EGRIFTA formulations for excess abdominal fat in adults with HIV-associated lipodystrophy. General weight-loss, anti-aging and compounded-wellness uses are separate from that approved indication.

Sermorelin is the active GHRH (1–29) fragment with a historical Geref diagnostic and pediatric-treatment record. Adult hormone responses and selected functional findings do not establish broad anti-aging, fat-loss or muscle-mass benefits.

Ipamorelin is an investigational pentapeptide acting through the ghrelin receptor. Short intravenous studies show GH release, while the postoperative-ileus trial missed its efficacy endpoint; marketed recovery, sleep and body-composition benefits remain unestablished.

Thymosin alpha-1 is a 28-amino-acid immunomodulatory peptide. It has disease-specific human studies and international product use, but mixed sepsis results do not establish general immune optimization or longevity benefit.

Selank is a synthetic tuftsin-derived heptapeptide investigated for anxiety, with small positive human comparisons and exploratory imaging/animal findings. Products, routes and outcomes differ; no FDA-approved treatment or universal regimen is established.

Semax is a synthetic ACTH-fragment-related heptapeptide used in Russia for neurological indications and studied in small human reports. Positive performance and stroke-rehabilitation findings remain limited by design and replication; it is not FDA-approved.